XML 126 R16.htm IDEA: XBRL DOCUMENT v3.24.1
SHARE CAPITAL AND RESERVES
12 Months Ended
Dec. 31, 2023
SHARE CAPITAL AND RESERVES  
SHARE CAPITAL AND RESERVES

11.

SHARE CAPITAL AND RESERVES

Authorized Share Capital

At December 31, 2023, the authorized share capital comprised an unlimited number of common shares. The common shares do not have a par value. All issued shares are fully paid.

Details of Common Shares Issued in 2023

    

Year ended 

    

Year ended 

December 31, 2023

December 31, 2022

    

Gross

    

    

Gross

Number of shares

 proceeds

Number of shares

proceeds

ATM program

3,552,224

$

22,980,338

500,229

$

2,549,677

Total

3,552,224

$

22,980,338

500,229

$

2,549,677

In August 2022, the Company filed a prospectus supplement to its short form base shelf prospectus, pursuant to which the Company may, at its discretion and from time-to-time, sell common shares of the Company for aggregate gross proceeds of up to US$100,000,000. The sale of common shares is to be made through “at-the-market distributions” (“ATM”), as defined in the Canadian Securities Administrators’ National Instrument 44-102 Shelf Distributions, directly on the TSX Venture Exchange and the NYSE American stock exchange. During the year ended December 31, 2023, the Company sold 3,552,224 (2022 – 500,229) common shares of the Company under the ATM program at an average price of $6.47 (2022 – $5.10) for gross proceeds of $22,980,338 (2022 - $2,549,677) or net proceeds of $22,440,215 (2022 - $2,489,754), and paid an aggregate commission of $540,123 (2022 - $59,923). At December 31, 2023, the Company completed $25,530,015 of the ATM program.

On November 6, 2023, the Company completed a bought-deal prospectus offering of 7,725,000 flow-through common shares at a price of $7.25 per common share for gross proceeds of $56,006,250. The Company paid share issuance costs of $2,977,254 in cash of which $2,357,908 was paid to the underwriters. The premium received on the flow-through shares issued was determined to be $15,295,500.

On November 2, 2023, the Company issued 39,762 common shares with a value of $203,979 pursuant to the acquisition of exploration and evaluation assets in accordance with the terms of certain property option agreements (Note 3).

During the year ended December 31, 2023, 178,500 stock options were exercised at a weighted average exercise price of $0.74 per share for gross proceeds of $131,630.

On December 14, 2022, the Company completed a bought-deal prospectus offering of 6,250,000 flow-through common shares at a price of $8.00 per common share for gross proceeds of $50,000,000. The Company paid share issuance costs of $2,717,627 in cash of which $2,104,250 was paid to the underwriters. The premium received on the flow-through shares issued was determined to be $14,500,000.

On November 16, 2022, the Company issued 39,762 common shares with a value of $194,834 pursuant to the acquisition of exploration and evaluation assets in accordance with the terms of certain property option agreements (Note 3).

During the year ended December 31, 2022, 4,341,875 stock options were exercised at a weighted average exercise price of $1.76 per share for gross proceeds of $7,649,906.

During the year ended December 31, 2022, 39,960 warrants were exercised at a weighted average exercise price of $1.38 per share for gross proceeds of $55,140.

11.

SHARE CAPITAL AND RESERVES (continued)

Share Purchase Option Compensation Plan

The Company has a share purchase option plan (the “Plan”) approved by the Company’s shareholders that allows it to grant share purchase options, subject to regulatory terms and approval, to its officers, directors, employees and service providers. The Plan is based on the maximum number of eligible shares not exceeding 10% in the aggregate and 5% with respect to any one optionee of the Company’s outstanding common shares in any twelve-month period. If outstanding share purchase options are exercised or expire, and/or the number of issued and outstanding common shares of the Company increases, then the share purchase options available to grant under the Plan increase proportionately. The exercise price and vesting terms of each share purchase option is set by the Board of Directors at the time of grant. Share purchase options granted are subject to a four-month hold period and exercisable for a period determined by the Board of Directors which cannot exceed ten years.

The continuity of share purchase options for the year ended December 31, 2023 is as follows:

    

    

Outstanding

    

    

    

Cancelled/

    

Outstanding

    

Exercisable

Exercise

December

Forfeited/

December

December

Expiry date

Price

31, 2022

Granted

Exercised

Expired

31, 2023

31, 2023

September 30, 2023

$

0.40

150,000

(150,000)

December 17, 2024

$

0.50

1,725,000

1,725,000

1,725,000

April 18, 2025

$

1.00

100,000

100,000

100,000

May 23, 2025

$

1.075

 

75,000

 

 

 

 

75,000

 

75,000

August 11, 2025

$

1.40

 

1,125,000

 

 

 

 

1,125,000

 

1,125,000

September 3, 2025

$

2.07

 

75,000

 

 

(25,000)

 

 

50,000

 

50,000

October 1, 2025

$

2.15

 

25,000

 

 

 

 

25,000

 

25,000

December 31, 2025

$

4.10

 

5,305,000

 

 

 

 

5,305,000

 

5,305,000

April 29, 2026

$

6.79

 

1,258,625

 

 

 

(295,750)

 

962,875

 

940,000

May 17, 2026

$

8.62

 

200,000

 

 

 

 

200,000

 

200,000

September 27, 2026

$

8.70

 

125,000

 

 

 

 

125,000

 

87,500

November 26, 2026

$

8.04

 

55,000

 

 

 

(7,500)

 

47,500

 

33,250

January 4, 2027

$

8.98

24,375

(1,875)

22,500

12,375

August 19, 2027

$

5.75

340,000

340,000

226,000

September 8, 2027

$

5.00

20,000

20,000

20,000

December 27, 2027

$

5.68

2,257,500

(3,500)

(97,750)

2,156,250

1,938,750

 

 

12,860,500

 

 

(178,500)

 

(402,875)

 

12,279,125

11,862,875

Weighted average exercise price $

 

4.01

 

 

0.74

 

6.55

 

3.97

 

3.89

Weighted average contractual remaining life (years)

 

 

3.24

 

 

 

 

2.25

 

2.20

11.

SHARE CAPITAL AND RESERVES (continued)

The continuity of share purchase options for the year ended December 31, 2022 is as follows:

    

    

Outstanding

    

    

    

Cancelled/

    

Outstanding

    

Exercisable

December

Forfeited/

December

December

Expiry date

Exercise Price

31, 2021

Granted

Exercised

Expired

31, 2022

31, 2022

September 30, 2023

$

0.40

150,000

150,000

150,000

December 17, 2024

$

0.50

1,925,000

(200,000)

1,725,000

1,725,000

April 18, 2025

$

1.00

1,450,000

(1,350,000)

100,000

100,000

May 23, 2025

$

1.075

200,000

 

 

(125,000)

 

 

75,000

 

75,000

August 11, 2025

$

1.40

2,900,000

 

 

(1,775,000)

 

 

1,125,000

 

1,125,000

September 3, 2025

$

2.07

115,000

 

 

(40,000)

 

 

75,000

 

75,000

October 1, 2025

$

2.15

25,000

 

 

 

 

25,000

 

25,000

December 31, 2025

$

4.10

6,155,000

 

 

(850,000)

 

 

5,305,000

 

5,305,000

April 29, 2026

$

6.79

1,294,250

 

 

(1,875)

 

(33,750)

 

1,258,625

 

1,168,625

May 17, 2026

$

8.62

200,000

 

 

 

 

200,000

200,000

September 27, 2026

$

8.70

125,000

 

 

 

 

125,000

 

50,000

November 26, 2026

$

8.04

55,750

(750)

55,000

22,000

January 4, 2027

$

8.98

30,000

(5,625)

24,375

7,500

August 19, 2027

$

5.75

340,000

340,000

169,000

September 8, 2027

$

5.00

 

20,000

 

 

 

20,000

 

10,000

December 27, 2027

$

5.68

2,257,500

2,257,500

1,834,500

14,595,000

2,647,500

(4,341,875)

(40,125)

12,860,500

12,041,625

Weighted average exercise price $

3.01

5.72

1.76

7.12

4.01

3.85

Weighted average contractual remaining life (years)

3.71

4.93

3.24

3.15

The table below summarizes the weighted average fair value of share purchase options granted and exercised:

    

Year ended December 31,

    

2023

    

2022

Weighted average:

Fair value of share purchase options granted

$

3.72

Fair value of share purchase options exercised

$

0.58

$

1.27

Closing share price at the date of exercise

$

5.75

$

6.36

Options were priced based on the Black-Scholes option pricing model using the following weighted average assumptions to estimate the fair value of options granted:

    

Year ended December 31, 

 

    

2023

    

2022

 

Risk-free interest rate

 

3.21

%

Expected option life in years

 

 

5.0

Expected share price volatility(i)

 

88.06

%

Grant date share price

$

5.39

Expected forfeiture rate

 

 

Expected dividend yield

 

 

Nil

(i)The expected share price volatility is based on the average historical share price of comparable companies over the life of the option.

11.

SHARE CAPITAL AND RESERVES (continued)

Warrants

The Company did not have any warrants outstanding as at December 31, 2023 and 2022.

The continuity of warrants for the year ended December 31, 2022 is as follows:

    

    

Outstanding

    

    

    

    

Outstanding 

Exercise

 December 

Cancelled/ 

December 31,

Expiry Date

 Price

31, 2021

Issued

Exercised

Expired

2022

May 12, 2022

$

1.30

 

25,154

 

 

(24,000)

 

(1,154)

 

May 13, 2022

$

1.50

 

8,372

 

 

 

(8,372)

 

June 4, 2022

$

1.50

 

15,960

 

 

(15,960)

 

 

 

 

49,486

 

 

(39,960)

 

(9,526)

Weighted average exercise price $

 

1.40

 

 

1.38

 

1.48

 

Weighted average contractual remaining life (years)

 

0.38

 

 

 

 

The table below summarizes the weighted average fair value of warrants exercised:

Year ended December 31,

    

2023

    

2022

Weighted average:

Fair value of warrants exercised

 

$

0.38

Closing share price at the date of exercise

 

$

8.39